Tarsus Pharmaceuticals (TARS) Insider Goldberg Sells 2,954 Shares

Andrew Goldberg Executes Share Disposition at Tarsus Pharmaceuticals

On June 12, 2026, Andrew Goldberg disposed of 2,954 shares of Tarsus Pharmaceuticals, Inc. (NasdaqGS: TARS). This transaction follows a series of recent insider moves at the commercial-stage biopharmaceutical enterprise, which focuses on eye care therapeutics like its flagship product XDEMVY for demodex blepharitis. Form 4 filings with the Securities and Exchange Commission capture these executive transactions, providing a transparent window into how leadership manages equity holdings.

Recent Insider Transactions and Executive Activity

The June 12 filing marked one of several trades executed on that date across the executive team. On the same day, Scott Morrison and Wendy Yarno also parted with 2,954 shares each, while Link William Phd acquired 2,954 shares. Goldberg himself has been active in the stock, previously acquiring 2,954 shares on June 12 and later picking up an additional 2,417 shares on June 25, 2026. Meanwhile, Katherine Goodrich sold 2,954 shares for $183,384.32 on June 15, 2026, at an average price of $62.08 per share under a planned trading program.

Tarsus Pharmaceuticals Stock Performance and Valuation

Tarsus Pharmaceuticals shares trade at $61.85, positioning the equity below its 50-day moving average of $69.16 and its 200-day moving average of $68.78. The biotechnology company carries a market capitalization of approximately $3.62 billion and a forward P/E ratio of 32.06. Over the past year, the stock has traded within a 52-week range spanning from a low of $53.89 to a high of $91.53, reflecting shifting sentiment across the healthcare sector as clinical programs advance.

Analysts Set New Price Targets

Wall Street firms continue to evaluate the biopharmaceutical firm's commercial rollout and pipeline candidates, which include treatments for ocular rosacea and the prevention of Lyme disease. On September 8, 2026, Jefferies maintained a buy rating while lifting its price target to $105.00 from $88.00. Oppenheimer kept an outperform rating on August 12, 2026, raising its target to $100.00. Earlier in the summer, Mizuho maintained an outperform rating with a $98.00 target, Guggenheim kept a buy rating at $89.00, and HC Wainwright & Co. reiterated a buy rating at $88.00.

Company Pipeline and Operational Focus

Tarsus Pharmaceuticals operates as a commercial-stage enterprise developing therapeutic candidates in Irvine, California. Its commercial efforts center on XDEMVY for demodex blepharitis, while its clinical pipeline features mid-stage trials for conditions such as ocular rosacea and Lyme disease prevention. The company reports a current ratio of 3.20 and maintains a debt-to-equity ratio of 25.61.

Upcoming Financial Milestones

Investors tracking the biotechnology firm look toward the next scheduled earnings report on November 4, 2026, for further updates on revenue growth and product adoption rates. These periodic SEC filings and disclosures offer historical context on insider participation without signaling directional shifts in corporate strategy.